Mark Leiser is a content strategist at Healio, specializing in hematology/oncology and cellular therapy. With a background in medical publishing since 2011, he focuses on various themes including oncology, immunotherapy, and wellness programs, aiming to provide valuable insights into medicine and healthcare. Leiser's work has been recognized in multiple prestigious awards, and he is featured in Healio.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Mark's coverage indicates a strong focus on healthcare and pharmaceuticals, particularly in the context of clinical trial data and scientific breakthroughs. He is most likely to be interested in pitches that provide access to exclusive data or insights related to new treatments for cancer, hemophilia, gene therapy, or other significant medical advancements.
Given Mark’s reliance on citing data, he may respond well to expert sources who can offer detailed analysis of clinical trial results or scientific developments in the mentioned fields. Pitches should emphasize the depth of expertise and ability to provide unique perspectives based on robust evidence.
It is important for potential contributors reaching out to Mark Leiser with relevant information regarding recent discoveries or groundbreaking research within these specialized areas.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Mark Leiser, Heather Biele
CHICAGO — Adding an immunotherapy-based regimen to standard treatment may improve outcomes for some patients with liver cancer who are not candidates for surgery, according to results of the randomized phase 3 EMERALD-3 study.
By: Heather Biele, Mark Leiser
CHICAGO — An interactive, case-based curriculum significantly improved hematology/oncology fellows' foundational knowledge of the specialty, according to study results presented at ASCO Annual Meeting.
By: Mark Leiser, Heather Biele
CHICAGO — Hematology/oncology fellows have embraced AI for educational or clinical purposes but they rarely receive formal training to guide use of these tools, according to survey results presented at ASCO Annual Meeting.
By: Heather Biele, Mark Leiser
CHICAGO — Pregnancy-associated cancer mortality in the United States has remained relatively unchanged despite the decline in national overall cancer death rates, according to findings presented at ASCO Annual Meeting.
By: Heather Biele, Mark Leiser
CHICAGO — Patient-facing resources about AI in cancer care are scarce, according to study results presented at ASCO Annual Meeting.
By: Heather Biele, Mark Leiser
First-time seizures are associated with significantly higher short-term risk for cancer — including malignancies that develop outside the central nervous system, according to results of a population-based cohort study.
By: Heather Biele, Mark Leiser
Video Player is loading. Play Video Play Mute Current Time Duration Loaded Stream Type LIVE
By: Mark Leiser, Heather Biele
Key takeaways: Ozekibart doubled median PFS and improved other outcomes vs. placebo in advanced conventional chondrosarcoma.
Persistent and prolonged drug shortages across the country are affecting delivery of care across well over 100 therapeutic areas, according to a new report.Shortages are lasting longer than ever, with the average duration now exceeding 5 years, the analysis from United States Pharmacopeia (USP) showed.
By: Mark Leiser, Heather Biele
Mesothelioma diagnoses and deaths continue to increase nationwide despite more than 5 decades of asbestos regulation and a halt on use of the mineral fibers for industrial purposes, according to study results.
